ParamergeParamerge

Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 Clinical Trial Optional)

National Institute on Drug Abuse (NIDA), NIH

Phased cooperative-agreement funding to develop and test interventions preventing or treating substance use disorders and overdose, including behavioral interventions and digital therapeutics alongside pharmacological and device approaches.

Indicative award
up to $3M per year (per year)Maximum $3 million in direct costs per year; no minimum published.
Timing
Several times a yearSeveral times a year · Feb, Jun, OctNo specific published date recorded. This funder publishes a cycle rather than a date, and this database does not invent one.Recurring cycles listed from October 20, 2025 through June 20, 2028, with the NOFO expiring August 22, 2028. The specific next cycle date was not confirmed on the fetched page.
Who can apply
Mid-career & senior, Any faculty rank
Eligibility
Higher education institutions, nonprofits with or without 501(c)(3) status, for-profits and small businesses, government and tribal agencies, faith- and community-based organizations, and foreign organizations (with restrictions on foreign subawards). Milestone-driven UG3-to-UH3 transition.
SSWR clusters
Topics
intervention development · overdose prevention · behavioral intervention · digital therapeutics · opioid and stimulant use
Apply at
https://grants.nih.gov/grants/guide/pa-files/PAR-25-446.html
This entry
Curated by the working group. Written 2026-08-07. The funder link has not yet been machine-checked.

Amounts and dates on this page are indicative and are maintained by people rather than scraped. Funders change ceilings, windows and eligibility without notice; confirm all details at the source above before applying.

← Back to the database